36 results about "17beta-hydroxysteroid dehydrogenase" patented technology

Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17beta-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17beta-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.

Fused tricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.

Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.

The present invention relates to a method of treating or preventing musculoskeletal pain in a mammal receiving administration of an estrogen. suppressant selected from the group consisting of aromatase inhibitors, GnRH analogues, cyclo-oxy-genase 2 (COX-2) inhibitors, 17β-hydroxysteroid dehydrogenase type 1 inhibitors, progestogens, anti-estrogens and combinations thereof, said method comprising the administration of an effective amount of an estrogenic component, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (1) in which formula R₁, R₂, R₃, R₄ independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.

Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds.

There is provided a compound of Formula I

wherein the various symbols are as defined in the description, and a method of manufacturing a medicament for use in the therapy of a condition or disease associated with 17β-hydroxysteroid dehydrogenase (17β-HSD), comprising a compound of Formula I.

The invention relates to 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) inhibitors, the preparation thereof and the use thereof for the treatment and prophylaxis of hormone-related, especially estrogen-related or androgen-related, diseases.

Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17β-hydroxysteroid dehydrogenase enzymes.

There are disclosed compounds of the formula (I):

prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.

The invention relates to a construction of a Comamonas testosteroni 3,17beta-HSD gene reinforced strain, and belongs to the microbial field. The construction of the Comamonas testosteroni 3,17beta-HSD gene reinforced strain is characterized in that a recombinant plasmid is pK-Tacpromoter-3,17beta-HSD; and the construction comprises the following steps: carrying out PCR technological amplification, and target segment recovery and purification of a Comamonas testosteroni genome which is a template to connect with a pUCm-T carrier; 2, carrying out PCR technological amplification, and target segment recovery and purification of a plasmid pAH10 which is a template to connect with the pUCm-T carrier; 3, extracting a recombinant plasmid 3,17beta-HSD-T through adopting a column plasmid DNA small-amount extraction kit; and 4, respectively extracting the recombinant plasmid and pK-3,17beta-HSD through adopting the column plasmid DNA small-amount extraction kit. According to the invention, the Comamonas testosteroni 3,17beta-HSD gene reinforced strain is constructed for the first time and is applied, and the estriol degradation efficiency, the cholesterol degradation efficiency and the stosterone degradation efficiency of the Comamonas testosteroni 3,17beta-HSD gene reinforced strain are 30%, 15% and 150% higher than that of a wild Comamonas testosteroni strain respectively.

Thiopheneprymidinone compounds useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.

This invention relates to novel substituted estratrien derivatives of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder requiring the inhibition of a 17beta-hydroxysteroid dehydrogenase (17beta- HSD) type 1, type 2 and/or type 3 enzyme, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds.

Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.

The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 2 (l7beta-HSD2) inhibitors of formula (I), their production and use, notably for the treatment and prophylaxis of sex steroid deficient diseases like osteoporosis in men and women.

This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17beta-hydroxysteroid dehydrogenase (17beta-HSD) such as 17beta-HSD type 1, type 2 or type 3 enzyme.

This invention relates to novel substituted thiophenepyrimidinone derivatives and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorder, such as steroid hormone dependent diseases or disorders requiring inhibition of 17beta-hydroxysteroid dehydrogenase enzymes.